Sort   by:  
 Page size 
TranscriptomicsTranscription profiling by array of Bacillus thuringiensis Bt407 overexpressing transcriptional regulator MogR versus an empty vector (pHT304-Pxyl) control strain during late exponential growth
Comparison in late exponential phase (culture OD600 = 3) of global expression profiles from a Bacillus thuringiensis 407 strain overexpressing transcriptional regulator MogR from xylose inducible vector pHT304-Pxyl, versus an isogenic empty vector control strain, to analyze global expression changes...
ORGANISM(S): Bacillus thuringiensis 
2020-09-28 | E-MTAB-7633 | biostudies-arrayexpress
TranscriptomicsTranscription profiling by array of Bacillus thuringiensis Bt407 overexpressing the diguanylate cyclase CdgF (BTB_c06420) versus an empty vector (pHT304-Pxyl) control strain 2 hours into post-exponential growth
Comparison of global expression profiles from a Bacillus thuringiensis 407 strain overexpressing the diguanylate cyclase CdgF (BTB_c06420) from the xylose inducible vector pHT304-Pxyl, versus an isogenic empty vector control strain, to analyze global expression changes resulting from CdgF overexpres...
ORGANISM(S): Bacillus thuringiensis Bt407 
2020-09-28 | E-MTAB-8898 | biostudies-arrayexpress
GenomicsWTCCC2 VL Brazil - samples
WTCCC2 Visceral Leishmaniasis samples from Brazil using Illumina 670k
EGAD00010000636 | EGA
GenomicsWTCCC2 VL Sduan - samples
WTCCC2 Visceral Leishmaniasis samples from Sudanl using Illumina 670k
EGAD00010000640 | EGA
GenomicsWTCCC2 VL India - samples
WTCCC2 Visceral Leishmaniasis samples from Indial using Illumina 670k
EGAD00010000638 | EGA
GenomicsWTCCC2 Visceral Leishmaniasis (VL) samples
A WTCCC2 project genome-wide association study for visceral leishmaniasis (VL) in individuals from India, Brazil and Sudan, genotyped on the custom Illumina 670k array. The WTCCC2 analysis of the Brazilian and Indian samples is described in Fakiola et al. [Nat Genet. 2013 Feb;45(2):208-13]. It shoul...
EGAS00001000773 | EGA
GenomicsWellcome Trust Case Control Consortium Data Access Committee
Access to summary data and individual-level genotype data is available by application to the Wellcome Trust Case Control Consortium Data Access Committee (CDAC). Access to data will be granted to qualified investigators for appropriate use. The CDAC also controls the individual level genotype data f...
EGAC00000000001 | EGA
UnknownAntibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune responses and breakthrough infections in patients with inflammatory bowel ...
S-EPMC8927425 | biostudies-literature
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.

Background

Anti-TNF drugs, such as infliximab, are associated with attenuated antibody responses after SARS-CoV-2 vaccination. We aimed to determine how the anti-TNF drug infliximab and the anti-integrin drug vedolizumab affect vaccine-induced neutralising antibodies against highly transmiss...
S-EPMC9757903 | biostudies-literature
UnknownFactors associated with D-dimer levels in HIV-infected individuals.

Background

Higher plasma D-dimer levels are strong predictors of mortality in HIV+ individuals. The factors associated with D-dimer levels during HIV infection, however, remain poorly understood.

Methods

In this cross-sectional study, participants in three randomized controlled trials...
S-EPMC3953205 | biostudies-literature
Sort   by:  
 Page size